|
Gene: MYO16 |
Gene summary for MYO16 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MYO16 | Gene ID | 23026 |
Gene name | myosin XVI | |
Gene Alias | MYAP3 | |
Cytomap | 13q33.3 | |
Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | F8W883 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23026 | MYO16 | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.71e-19 | 4.16e-01 | 0.0155 |
23026 | MYO16 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.08e-11 | 3.79e-01 | -0.1808 |
23026 | MYO16 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.99e-05 | 4.75e-01 | 0.0216 |
23026 | MYO16 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.37e-20 | 6.00e-01 | -0.0811 |
23026 | MYO16 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.96e-10 | 2.96e-01 | -0.1088 |
23026 | MYO16 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.74e-37 | 6.42e-01 | -0.1954 |
23026 | MYO16 | HTA11_411_2000001011 | Human | Colorectum | SER | 3.57e-07 | 6.15e-01 | -0.2602 |
23026 | MYO16 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.63e-15 | 5.39e-01 | -0.1207 |
23026 | MYO16 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.74e-08 | 3.68e-01 | -0.1526 |
23026 | MYO16 | HTA11_696_2000001011 | Human | Colorectum | AD | 6.34e-26 | 5.35e-01 | -0.1464 |
23026 | MYO16 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.01e-09 | 2.05e-01 | -0.1001 |
23026 | MYO16 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.29e-15 | 4.05e-01 | -0.059 |
23026 | MYO16 | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.54e-14 | 6.26e-01 | -0.1706 |
23026 | MYO16 | HTA11_5212_2000001011 | Human | Colorectum | AD | 6.06e-15 | 6.36e-01 | -0.2061 |
23026 | MYO16 | HTA11_5216_2000001011 | Human | Colorectum | SER | 9.51e-21 | 1.03e+00 | -0.1462 |
23026 | MYO16 | HTA11_546_2000001011 | Human | Colorectum | AD | 9.74e-11 | 5.15e-01 | -0.0842 |
23026 | MYO16 | HTA11_6818_2000001011 | Human | Colorectum | AD | 2.03e-03 | 2.76e-01 | 0.0112 |
23026 | MYO16 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.57e-03 | 1.54e-01 | 0.0588 |
23026 | MYO16 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.75e-03 | 1.43e-01 | 0.294 |
23026 | MYO16 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 6.02e-23 | 6.56e-01 | 0.281 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0007346 | Colorectum | AD | regulation of mitotic cell cycle | 119/3918 | 457/18723 | 4.60e-03 | 3.14e-02 | 119 |
GO:0048017 | Colorectum | AD | inositol lipid-mediated signaling | 53/3918 | 182/18723 | 5.35e-03 | 3.52e-02 | 53 |
GO:0048015 | Colorectum | AD | phosphatidylinositol-mediated signaling | 52/3918 | 178/18723 | 5.37e-03 | 3.54e-02 | 52 |
GO:00480171 | Colorectum | SER | inositol lipid-mediated signaling | 42/2897 | 182/18723 | 4.36e-03 | 3.49e-02 | 42 |
GO:00480151 | Colorectum | SER | phosphatidylinositol-mediated signaling | 41/2897 | 178/18723 | 4.97e-03 | 3.86e-02 | 41 |
GO:00073461 | Colorectum | MSS | regulation of mitotic cell cycle | 108/3467 | 457/18723 | 3.30e-03 | 2.50e-02 | 108 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MYO16 | SNV | Missense_Mutation | novel | c.3923N>C | p.Ser1308Thr | p.S1308T | protein_coding | tolerated(0.06) | benign(0.119) | TCGA-56-8628-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
MYO16 | SNV | Missense_Mutation | rs377315850 | c.3868G>A | p.Val1290Ile | p.V1290I | protein_coding | tolerated(0.08) | benign(0.021) | TCGA-56-A49D-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
MYO16 | SNV | Missense_Mutation | rs137956492 | c.3724N>A | p.Ala1242Thr | p.A1242T | protein_coding | tolerated(0.13) | benign(0.001) | TCGA-56-A5DS-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MYO16 | SNV | Missense_Mutation | novel | c.3499N>A | p.Leu1167Ile | p.L1167I | protein_coding | tolerated(0.33) | benign(0.35) | TCGA-56-A62T-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | CR | |
MYO16 | SNV | Missense_Mutation | rs752075568 | c.97C>T | p.Leu33Phe | p.L33F | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-60-2703-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
MYO16 | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | protein_coding | tolerated(0.05) | possibly_damaging(0.69) | TCGA-60-2714-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | SD | |
MYO16 | SNV | Missense_Mutation | c.5593N>T | p.Gly1865Trp | p.G1865W | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-66-2744-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
MYO16 | SNV | Missense_Mutation | novel | c.5181N>A | p.Met1727Ile | p.M1727I | protein_coding | tolerated_low_confidence(0.36) | benign(0.228) | TCGA-68-7757-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
MYO16 | SNV | Missense_Mutation | c.100N>A | p.Pro34Thr | p.P34T | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-6A-AB49-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
MYO16 | SNV | Missense_Mutation | novel | c.101N>A | p.Pro34His | p.P34H | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-6A-AB49-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |